of the surface envelope glycoprotein with the cell receptor.
Galactans from red seaweeds have structures based on a linear chain of alternating 3-linked β-D-galactopyranose residues (A units) and 4-linked α-Dor α-L-galactopyranose residues or its 3,6-anhydro derivative (B units) . The main classification of these galactans is made in carrageenans, when the B unit belongs to the D-series, and agarans, when the B unit is in the L-configuration (Figure 1 ). Carrageenans cover a broad dispersion of structures that have been grouped into three major types, namely kappa/iota-, mu/nu-and lambda-carrageenans, whereas agarans are not systematically classified (Duckworth & Yaphe, 1971 ). This clear-cut separation between carrageenans and agarans has been upset by the finding of a third group, named DL-galactan hybrids, in which the B units can have D-and L-configurations in the same molecule (Figure 1 ). According to the proportion of B units in the D-or L-configuration, the DL-galactan hybrids were divided into carrageenan DL-hybrids (major amount of D-type) and agaran DL-hybrids (major amount of L-type) (Stortz & Cerezo, 2000) . When a hot water extract of the red seaweed Gymnogongrus torulosus was submitted to fractionation and enantiomeric analysis of the fractions, the system of galactans biosynthesized by the seaweed was mainly composed by carrageenan DL-hybrids, with minor quantities of agarans (Estevez et al., 2001) .
Both carrageenans and agarans are known as highly selective inhibitors of various enveloped viruses, including HIV, herpes simplex virus (HSV) and cytomegalovirus (González et al., 1987; Nakashima et al., 1987; Baba et al., 1988; Carlucci et al., 1997; Cáceres et al., 2000; Yamada et al., 2000) . The inhibitory action of this kind of compounds, as reported for other sulfated polysaccharides, has been ascribed to the interference in the initial interaction of virus glycoproteins with the cell surface heparan sulphate (Witvrouw & de Clercq, 1997; Carlucci et al., 1999) . The lack of information about the biological properties of DL-hybrid molecules prompted us to study the antiviral activity of the DL-galactan hybrids of the carrageenan-and agaran-types isolated from the red seaweed Gymnogongrus torulosus. The present study was undertaken using HSV type 2 (HSV-2), a virus known as very sensitive to the action of polyanionic compounds in general (Witvrouw et al., 1994) and carrageenans in particular (Carlucci et al., 1997) , and Dengue virus type 2 (DEN-2), a flavivirus that binds to a highly sulphated type of heparan sulphate in the cell surface (Chen et al., 1997) .
Novel DL-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus A novel series of DL-galactan hybrids extracted from the red seaweed Gymnogongrus torulosus, was evaluated for its in vitro antiviral properties against herpes simplex virus type 2 (HSV-2) and dengue virus 2 (DEN-2). These compounds were very active against both viruses with inhibitory concentration 50% (IC 50 ) values in the range 0.6-16 µg/ml for HSV-2 and 0.19-1.7 µg/ml for DEN-2, respectively, as determined in a virus plaque reduction assay in Vero cells. The DL-galactans lacked of cytotoxic effects, on stationary as well as on actively dividing cells, and anticoagulant properties. Some of the compounds showed a variable level of direct inactivating effect on both virions, with virucidal concentration 50% values exceeding the IC 50 s obtained by plaque reduction assay. Full inhibitory activity was achieved when the galactans were present during virus adsorption period, suggesting that the mode of action of these compounds is an interference in the binding Introduction Antiviral Chemistry & Chemotherapy 13:83-89
The potential of this kind of molecules that block the initial virus adsorption to the target cell as inhibitors of dengue virus, a re-emerging pathogen and agent of the most prevalent arthropod-borne viral disease in humans (Gubler, 1998) , is discussed.
Materials and methods

Polysaccharides
Extraction of the polysaccharides and their fractionation were described previously (Estevez et al., 2001) : The four extracts (C1-C4) initially obtained contained galactose and 3,6-anhydrogalactose as major sugars, both present in the D-and L-configurations. Potassium chloride fractionation of C1 produced fractions F1-F3, also containing galactose and 3,6-anhydrogalactose, both sugars in the D-and L-configuration in F1 and F3, whereas only D-galactose was present in F2. F3, soluble in 2M KCl, was submitted to alkaline treatment and the resulting product (F3T) was again fractionated with increasing concentrations of potassium chloride, giving F3T1-F3T6. F3T1 insolubilized during the purification-dialysis procedure, and F3T3 and F3T5 were obtained in very small yields. The remaining three fractions F3T2, F3T4 and F3T6 again contained both sugars in the D-and L-forms. In summary, F3 and F3T6 are mixtures, while F1, F2, F3T2 and F3T4 are homogeneous compounds, both sets composed by DL-galactan 
Cells and viruses
Vero (African green monkey kidney) cells were grown in Eagle's minimum essential medium (MEM) supplemented with 5% calf serum. For maintenance medium (MM), the serum concentration was reduced to 1.5%. The C6/36 mosquito cell line from Aedes albopictus was cultured at 28°C in L-15 Medium (Leibovitz) supplemented with 0.3% tryptose phosphate broth, 0.02% glutamine, 1% MEM non-essential amino acids solution and 5% fetal calf serum.
Dengue virus type 2 strain NGC was obtained from the Instituto Nacional de Enfermedades Virales Humanas (INEVH) Dr J Maiztegui, Pergamino, Argentina. DEN-2 stocks were prepared in C6/36 cells and titrated by plaque formation in Vero cells. HSV-2 strain G, obtained from the American Type Culture Collection (Rockville, USA), was propagated and titrated in Vero cells.
Cytotoxicity determinations
Vero cell viability was measured by the MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Sigma Aldrich) method. Two types of assay were done, in preformed monolayers of Vero cells and in actively dividing cells. For preformed monolayer cell assay, confluent cultures in 96-well plates were exposed to different concentrations of the polysaccharides, with three wells for each concentration, using incubation conditions equivalent to those used in the antiviral assays. Then 10 µl of MM containing MTT (final concentration 5 µg/ml) was added to each well. After 2 h of incubation at 37°C, the supernatant was removed and 200 µl of ethanol was added to each well to solubilize the formazan crystals. After vigorous shaking, absorbance was measured in a microplate reader at 595 nm. The cytotoxic concentration 50% (CC 50 ) was calculated as the compound concentration required to reduce cell viability by 50%.
The actively dividing cell assay consisted of seeding 96-well micoplates with cells and letting them attach for 3 h. Then, polysaccharides were added, and the assay continued as with preformed monolayer cultures.
Virus plaque reduction assay
Antiviral activity was evaluated by a virus plaque reduction assay. Vero cell monolayers grown in 24-well plates were infected with about 50 plaque forming units (PFU)/well in the absence or presence of various concentrations of the compounds. After 1 h of adsorption at 37°C, residual inoculum was replaced by MM containing 0.7% methylcellulose and the corresponding dose of each compound. Plaques were counted after 2 days of incubation at 37°C for HSV-2, or after 7 days for DEN-2. The inhibitory concentration 50% (IC 50 ) was calculated as the compound concentration required to reduce virus plaques by 50%. All determinations were performed twice and each in duplicate.
Virucidal assay
A virus suspension of HSV-2 or DEN-2 containing 4×10 5 PFU was incubated with an equal volume of MM with or without various concentrations of the compounds for 1 h at 37°C. The samples were then diluted in cold MM to determine residual infectivity by plaque formation. The sample dilution effectively reduced the drug concentration to be incubated with the cells at least 100-fold to assess that titre reduction was only due to cell-free virion inactivation. The virucidal concentration 50% (VC 50 ), defined as the concentration required to inactivate virions by 50% was then calculated.
Effect of the incubation time on the antiviral activity
Vero cells grown in 24-well plates were infected with 50 PFU of HSV-2 or DEN-2 under different treatment conditions: exposure to different concentrations of the galactans was restricted to the virus adsorption phase only (compound in the inoculum), or to adsorption and postadsorption (compound in the inoculum and in the plaquing medium) or to the post-adsorption period only (in the plaquing medium). After 2 or 7 days of incubation at 37°C for HSV-2 and DEN-2, respectively, plaques were counted and the IC 50 values were calculated for each treatment.
Virus internalization assay
Vero cells were infected with HSV-2 or DEN-2 at a multiplicity of infection (m.o.i.) of 1. After 1 h adsorption at 4°C, cells were further incubated for 1 h at 37°C to allow virus internalization in the presence or the absence of 20 µg/ml of the galactans. Then, cultures were washed with PBS, and citrate buffer (citric acid 40 mM, potassium chloride 10 mM, sodium chloride 135 mM, pH 3) was added to inactivate adsorbed but not internalized virus. Later, cells were washed with PBS and resuspended by the addition of trypsin. The protease was then inactivated by adding phenyl-methyl-sulphonyl fluoride in PBS containing 3% bovine serum albumin. Cells were then pelleted by centrifugation and internalized virus was quantitated by an infectious centre assay.
Assay for anticoagulant activity
The thrombin time (TT) was measured using pooled human plasma and various concentrations of the compounds. Human plasma (170 µl) and test sample (30 µl) were mixed, and incubated at 37°C for 2 min. Bovine thrombin (Sigma Chemical Co; 7.5 units/ml, 100 µl) was added to the mixture and the time to clot formation was recorded.
Results
The structure of the sulfated polysaccharides used in this paper is described elsewhere (Estevez et al., 2001) and is summarized in Table 1 .
The antiviral activity of these compounds against HSV-2 and DEN-2 was evaluated in Vero cells by a virus plaque reduction assay. As shown in Table 2 , all the compounds were very active against HSV-2, with IC 50 values in the range 0.6-16 µg/ml. When the antiviral assay was performed against DEN-2, most of the compounds showed a higher level of effectiveness compared to HSV-2, with values of IC 50 ranging from 0.19 to 1.7 µg/ml. For comparative purposes of the antiviral potential of the DL-hybrids with those of carrageenans, commercial 'pure' kappa-and iota-carrageenans were used as reference substances. In general, as seen in Table 2 , DL-hybrids from G. torulosus were similarly or more active than commercial carrageenans, with the only exception of F3T6, which was significantly less inhibitory against HSV-2 than the commercial compounds.
No cytotoxicity was observed with any of the galactans when cell viability was evaluated in preformed monolayers of Vero cells in the presence of concentrations up to 1000 µg/ml, with the only exception of F3T4, which exhibited a CC 50 value of 822 µg/ml. Thus, the evaluation of the selectivity index (ratio CC 50 /IC 50 ) revealed very high values for all the compounds (range of selectivity indices 64-1587 for HSV-2 and 592-5263 for DEN-2, respectively). To assess the lack of cytotoxicity of these galactans, their effects on cell proliferation of actively dividing cells were also evaluated. The viability of proliferating cells after exposure to the galactans, added 3 h after seeding, compared well with that obtained in confluent preformed monolayers of Vero cells, with CC 50 values higher than 1000 µg/ml.
In order to analyse the possibility that these polysaccharides may act directly on the virus particle leading to infectivity inactivation, a virucidal assay against HSV-2 and DEN-2 virions was carried out. Four fractions, C2, F1, F3T2 and F3T6, were unable to inactivate HSV-2 virions at concentrations up to 100 µg/ml ( Table 2 ). The remaining six galactans showed a weak virucidal effect on HSV-2 virions with VC 50 values highly exceeding the corresponding antiviral IC 50 values. The ratios between VC 50 and IC 50 were in the range 21.9-94.3, indicating that the inhibitory effect detected by the plaque reduction assay was really due to interference with some step of the HSV-2 replication cycle. Results obtained when the virucidal assay was performed against DEN-2 showed that the galactans C2 and F3T6 were inactive, as occurred with HSV-2, but the other compounds exhibited an important virucidal effect with VC 50 values ranging from 1.6 to 8.9 µg/ml ( Table 2) . Consequently the VC 50 values for these compounds against DEN-2 were 4.5-17.9 higher than the IC 50 values, suggesting that the inactivating capacity may be partially responsible of the reduction observed in the plaque formation assay with DEN-2.
Three active fractions representative of each step of the extraction procedure (C1, F3 and F3T4) were chosen for further characterization.
The inhibitory effect of the DL-galactan hybrids against HSV-2 and DEN-2 was totally dependent on the presence of the compounds during the initial virus adsorption to the cell. When the plaque reduction assay was performed omitting the presence of the galactans in the adsorption period and including the compounds only in the plaquing medium after adsorption, no significant reduction in the number of virus plaques was detected, even at concentrations as high as 50 µg/ml (Table 3) . By contrast, the presence of these compounds only at virus adsorption was as effective as the treatment throughout the whole incubation period, during and after adsorption (Table 3 ). This finding suggests that the main target of the DL-galactan hybrids is the binding of virus to the host cell receptor. The effects of DL-galactans were not reversible, since the withdrawal of the compounds after adsorption did not affect the antiviral activity (Table 3) . The possible effect of the galactans on the subsequent stage of the virus cycle was studied by analysing the effect of C1, F3 and F3T4 on virus internalization. Neither compound prevented penetration of HSV-2 and DEN-2 since the amount of internalized virus, was similar in polysaccharides-treated and control infected cells (data not shown).
As the antiviral perspectives of several polysaccharides are hampered by their blood clotting ability, the DL-galactan hybrids were evaluated for their anticoagulant activity by measuring the TT. Treatment of blood with the different compounds at a concentration near the IC 50 , such as 0.5 µg/ml did not significantly change the TT value (Table 4 ). Only C3, F1, F2 and F3 had TT values slightly higher than plasma treated with saline (14.6 s). A galactan concentration as high as 100 µg/ml, on average 150 times higher than the IC 50 against DEN-2, was necessary to only duplicate or, in some cases, triplicate the TT value. It must be remarked that F3T2, the most active inhibitor of DEN-2 with an IC 50 of 0.2 µg/ml (Table 2) showed a negligible variation in the TT value (14.4-18.7 s) in the range of concentrations 0.5-100 µg/ml (Table 4 ). However, 0.5 µg/ml of heparin showed a TT greater than 180 s.
Discussion
The new group of DL-galactan hybrids isolated from G. torulosus showed a very selective and potent antiviral action against both HSV-2 and DEN-2, without cytotoxic effects and significant anticoagulant properties. Full inhibitory activity was achieved only when the galactans were present during virus adsorption period, suggesting that the mode of action of these compounds is interference with the binding of the surface envelope glycoprotein with the cell receptor. Both viruses, HSV-2 and DEN-2, use the heparan sulfate of cellular proteoglycans as the primary receptor (WuDunn & Spear, 1989; Chen et al., 1997; Putnak et al., 1997) . Noticeably, the flavivirus DEN-2 was more susceptible to the action of the galactans than HSV-2, in plaque reduction tests as well as in virucidal assays, with selectivity indices against DEN-2 about 5000 for the most active compounds. A differential inhibitory effect of sulfated polysaccharides and other polymers on the replication of myxoviruses and retroviruses has been reported and attributed to variations in the amino acid sequences of the viral envelope glycoproteins that are involved in virus-cell binding (Hosoya et al., 1991) . The knowledge of the precise heparan sulfate binding domain in the viral attachment proteins, the glycoprotein C (gC) of HSV-2 and the glycoprotein E of DEN-2, is not totally elucidated (Trybala et al., 1994; Tal-Singer et al., 1995; Chen et al., 1997; Thullier et al., 2001 ) and it will be necessary to establish the basis of the high susceptibility of DEN-2.
No conclusive structure-activity relationships can be established at present. The extracts C1-C4 and the fractions F3 and F3T6 are mixtures of DL-galactan hybrids with different types of structures (Estevez et al., 2001) , then it is impossible to make any correlation between structure and activity. F1 and F2 are kappa/iota-carrageenan DL-hybrids sulfated on C-4 of the β-D-galactose residue of the carrageenan-and the agaran-structural units. It was previously demonstrated that the presence of sulfate on this position is responsible for the antiviral activity of kappa-carrageenans (Carlucci et al., 1997 (Carlucci et al., , 1999 . Some units were also sulphated on C-2 of the 3,6-anhydrogalactose residues. F3T2 and F3T4 are DL-galactan hybrids with similar percentages of carrageenan and agaran structures, both sulphated, as above, on C-4 of the β-units, although F3T4 has higher amounts of 3,6-anhydrogalactose units sulphated on C-2. The difference in the antiviral activity of the standard kappa-and iota-carrageenans against HSV-2 suggests that the sulphate groups on C-2 of the 3,6-anhydrogalactose units are responsible for the higher activity found for iotacarrageenan; this difference was not observed against DEN-2 (Table 1) . A similar behaviour was observed for F3T2 and F3T4. It has been supposed that the carrageenan-agaran domains in a DL-galactan hydrid correspond to junction zones in a block copolymer (Figure 1 ; Estevez et al., 2001) . This hypothesis of the block copolymer is consistent with the high antiviral activity of the DL-galactan hybrids, since an extended zone of regular sulphation is required for viral inhibition. The results presented here allow the inclusion of a new type of molecule in the group of sulphated polysaccharides, previously known as inhibitors of herpesviruses (Witvrouw et al., 1994) . Nevertheless, the most remarkable finding is the strong inhibitory effect of these compounds against DEN-2, a human pathogen that has reemerged as an increasingly important public health threat (Igarashi, 1997; Gubler, 1998) . There is no specific treatment for infection caused by dengue virus, or any other flavivirus. Chen et al. (1997) demonstrated that dengue viruses use heparan sulphate to enter cells and two sulphated polysaccharides, heparin and suramin, were found to prevent dengue virus infection of target cells. The neutralizing activity of dextran sulfate against hepatitis C virus, another human pathogen member of the family Flaviviridae, has also been reported (Cribier et al., 1998) . Our results encourage the perspectives of the use of polysulphates against flavivirus infections.
